From: Mantle cell lymphoma and its management: where are we now?
Target | Study | Setting | Phase | Regimen | ORR | CR | PFS | OS |
---|---|---|---|---|---|---|---|---|
1 | Proteasome inhibitor | |||||||
Fisher et al. [33] | Relapsed | I/II | V | 33% | 8% | NA | NA | |
Ruan et al. [34] | Front line | I/II | V + RCHOP | 91% | 64% | 23 months | NR | |
Till BG et al. [36] | Front line | II | V + RCHOP | 83% | 57% | 29.5 months | NR | |
Chang et al. [37] | Front line | II | V + Modified R-HyperCVAD (VcR-CVAD) and MR for 5 years | 90% | 77% | 8.14 years | NR | |
2 | Bruton’s tyrosine kinase inhibitor | |||||||
Rule et al. [40] | Relapsed/refractory | PA | Ibrutinib monotherapy | 69.7% | 26.5% | 13Â months | 26.7Â months | |
Wang et al. [41] | Relapsed/refractory | II | Ibrutinib + R | 88% | 44% | 75% (12 months) | 85.5% (12 months) | |
Maddocks et al. [42] | Relapsed or new MCL | I/Ib | Ibrutinib + BR | 94% | 76% | NA | NA | |
Wang et al. [44] | Relapsed | II | Acalabrutinib | 81% | 40% | 67% (12Â months) | 87% (12Â months) | |
Walter et al. [45] | Relapsed | I | ONO/GS-4059 | 92% | 46% | NA | NA | |
Tam et al. [46] | Relapsed | II | Ibrutinib+venetoclax | 71% | 62% | NA | NA | |
3 | Epigenetic agents | |||||||
Pu et al. [48] | New or relapsed/refractory MCL | I/II | Cladribine + R + V | 85% | 77% | NR | NR | |
Spurgeon et al. [47] | New or relapsed MCL, CLL, NHL | II | Vorinostat + Cladribine + R | 97% (untreated MCL) | 80% (untreated MCL) | 70.7% (24 months) | 86% (24 months) | |
Puvvada et al. [49] | New or relapsed MCL and indolent NHL | II | Cladribine + R + V | 100% | 50% | 82% (24 months) | 91% (24 months) | |
4 | Immunomodulatory agent | |||||||
Goy et al. [50] | Relapsed | II | Len monotherapy | 28% | 7.5% | 4 mon | 19 mon | |
Habermann et al. [51] | Relapsed | II | Len monotherapy | 53% | 20% | 5.6 mon | NA | |
Witzig et al. [52] | Relapsed | II | Len monotherapy | 42% | 21% | 5.7 mon | NA | |
Wang et al. [54] | Relapsed/refractory | I/II | Len + R | 57% | 36% | 11.1 mon | 24.3 months | |
First line | II | Len + R | 92% | 64% | Not reached | 97% (2 years OS) | ||
Morrison et al. [53] | Relapsed/refractory | II | Len + V | 39.6% | 15.1% | 7 months | 26 months | |
Albertsson-Lindblad et al. [57] | First line | I/II | Len + BR | 91% | 78% | 42 months | 53 months | |
5 | mTOR kinase inhibitors | |||||||
Hess et al. [58] | Relapsed/refractory | III | Temsirolimus vs. investigator’s choice | 6–22% | 0–2% | 4.8–3.4 months | 12.8–10 months | |
Witzig et al. [59] | Relapsed | II | Temsirolimus monotherapy | 30% | 3% | 6.5Â months | 12Â months | |
Ansell et al. [60] | Relapsed | II | Temsirolimus monotherapy | 41% | 3.7% | 6Â months | NA | |
Wang et al. [62] | Refractory to V | II | Everolimus monotherapy | 8.6% | 0% | 4.4Â months | 16.9Â months | |
Hess et al. [61] | Relapsed | I | Temsirolimus + BR | 92% | 45% | NA | NA | |
6 | CART and BiTE | |||||||
Abramson et al. [66] | Relapse/refractory | Pivotal trial | Lisocabtagene maraleucel (JCAR017) | 72% (NHL) | 52% (NHL) | NA | NA | |
ZUMA-2 [68] | Relapsed/refractory | II | Axicabtagene ciloleucel | NA | NA | NA | NA | |
Goebeler et al. [69] | Relapsed/refractory | I | Blinatumomab | 71% | NA | NA | NA | |
Dufner et al. [70] | Relapsed/refractory | I | Blinatumomab | NA | NA | 204Â days | 1560Â days | |
Budde et al. [71] | Relapsed/refractory | I | Mosunetuzumab | 41% | NA | NA | NA |